Tarrytown-headquartered Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is collaborating with Celularity Inc. (NASDAQ:CELU) a Florham Park, New Jersey-based biotechnology company, in a multi-year agreement focused on allogeneic cell therapy candidates.
The initial focus of this partnership involves research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. The research will take place at Celularity”™s state-of-the-art facility. The financial terms of this endeavor were not disclosed.
“The agreement with Regeneron announced today is an important milestone for Celularity that recognizes our expertise in the research of cellular therapies, including the engineering of CAR-T cells,” said Dr. Robert J. Hariri, Celularity”™s CEO, chairman and founder. “We believe that this relationship paves the way for future industry collaborations leveraging our world class cell therapy facilities and capabilities. We have long admired the exceptional scientific legacy at Regeneron and welcome the opportunity to collaborate with a world leader in innovative medicines.”
